KYMR Kymera Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
03:33
Aug 21
Aug 21
Author argues CRVS is an easier short due to enrollment games.
Author argues CRVS is an easier short due to enrollment games, while KYMR is only mentioned as context without a directional call.
LOW
02:31
Aug 21
Aug 21
KYMR pre-readout analysis, no directional stance.
Analyzes KYMR ahead of BROADEN2 AtD readout, presenting bull/bear cases, outcome probabilities, and valuation concerns without committing to a directional trade.
MED
23:38
Aug 19
Aug 19
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
Aug 19
Aug 19
Upcoming year-end binary data catalysts noted
Highlights upcoming year-end data catalysts for these biotech names, providing estimated upside and downside scenarios.
MED
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position.
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
10:54
Jun 26
Jun 26
Author asserts KYMR appears more valuable than APGE on a relative valuation basis.
Author asserts KYMR appears more valuable than APGE on a relative valuation basis, in context of APGE's $11B acquisition.
MED
00:32
Jun 23
Jun 23
The author mocks a corporate slide from Kymera Therapeutics for a poor before-and-after.
The author mocks a corporate slide from Kymera Therapeutics for a poor before-and-after comparison, expressing skepticism but not a trade position.
LOW
00:32
Jun 23
Jun 23
The tweet reports market cap increases for KYMR and NKTR without expressing a personal position.
The tweet reports market cap increases for KYMR and NKTR without expressing a personal position or forward-looking trade view.
LOW
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:42
Jun 19
Jun 19
Co-mentioned as part of atopic dermatitis basket expected to benefit from the APGE M&A deal.
Co-mentioned as part of atopic dermatitis basket expected to benefit from the APGE M&A deal read-through; no specific thesis beyond sector lift.
MED
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers.
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
00:16
Jun 15
Jun 15
Named as potential public AtD takeout candidates if BP shifts acquisition strategy.
Named as potential public AtD takeout candidates if BP shifts acquisition strategy from privates to public companies; author frames as speculative question.
MED
19:10
Jan 04
Jan 04
KYMR cited as a competitive threat capable of displacing CRVS more than injectable biologics.
KYMR cited as a competitive threat capable of displacing CRVS more than injectable biologics; no direct bullish position stated by author.
LOW
About KYMR Analyst Coverage
Buzzberg tracks KYMR (Kymera Therapeutics, Inc.) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (6%). 16 total trade ideas tracked. Latest voices: seedy19tron, A May MD.